Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-three
- Development stage
- Phase 4
- Lead developer
- Toa Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bio-three is a symbiotic probiotic preparation composed of three distinct bacterial strains: *Bacillus mesentericus* TO-A, *Clostridium butyricum* TO-A, and *Enterococcus faecalis* T-110. Developed by Toa Pharmaceutical, this combination is designed to optimize the intestinal environment through a synergistic relationship where *B. mesentericus* promotes the growth of the other two strains. *C. butyricum* is a significant producer of butyric acid, a short-chain fatty acid (SCFA) that provides energy to colonocytes, maintains mucosal integrity, and exerts anti-inflammatory effects by inhibiting histone deacetylases and activating G-protein coupled receptors like GPR43. *E. faecalis* produces lactic acid, which lowers intestinal pH to inhibit the growth of pathogenic bacteria. Bio-three is primarily used for the treatment of gastrointestinal disturbances, including diarrhea, constipation, and irritable bowel syndrome, and is increasingly investigated for its role in modulating the gut-immune axis.
- Brand names
- Bio-threeBio-Three HiBio-Three Plus
- Other names
- Bio-3Bio3Bio 3Bacillus mesentericus, Clostridium butyricum, and Enterococcus faecalis combination
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Bio-three.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-three.